Evidence map›Paper›PMID 30213230›Full record

ArticleMolecular imaging

The Binding of BF-227-Like Benzoxazoles to Human α-Synuclein and Amyloid β Peptide Fibrils.

Lee Josephson, Nancy Stratman, YuTing Liu, Fang Qian, Steven H Liang, Neil Vasdev, Shil Patel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. PET imaging of alpha-synuclein: from radiotracer design through in vitro and in vivo translation.European journal of nuclear medicine and molecular imaging · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lee Josephson1 MedChem Imaging, LLC, Boston, MA, USA.
Nancy Stratman3 Biomarkers Preclinical Imaging and Pharmacology, Research and Early Development, Biogen, MA, USA.
YuTing Liu4 Biologics Drug Discovery, Biogen, Cambridge, MA, USA.
Fang Qian4 Biologics Drug Discovery, Biogen, Cambridge, MA, USA.
Steven H Liang2 Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Neil Vasdev1 MedChem Imaging, LLC, Boston, MA, USA.
Shil Patel5 Translational Imaging Engine, Eisai AiM Institute, MA, USA. Vasdev is now with Azrieli Centre for Neuro-Radiochemistry, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of an α-synuclein (α-Syn) positron emission tomography agent for the diagnosis and evaluation of Parkinson disease therapy is a key goal of neurodegenerative disease research. BF-227 has been described as an α-Syn binder and hence was employed as a lead to generate a library of α-Syn-binding compounds. [

Indexed as

alpha-SynucleinAmyloid beta-PeptidesBenzoxazolesHumansProtein BindingReference StandardsThiazoles2-(2-(2-dimethylaminothiazol-5-yl)ethenyl)-6-(2-(fluoro)ethoxy)benzoxazolealpha-SynucleinAmyloid beta-PeptidesBenzoxazolesSNCA protein, humanThiazolesamyloid β peptideBF-227binding affinityfibrilsPETα-synuclein

Identifiers

PMID30213230
PMCPMC6144582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.